Clinical Trial Update: Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update for an anti-CD19 CAR-T cell therapy in B cell malignancies has completed recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Lymphocytic Leukemia
• Lymphoma

Snippet

Sponsor: Shenzhen Institute for Innovation and Translational Medicine | Conditions: Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1, Phase 2 | Status: COMPLETED